Alnylam Pharmace. buy tamam
Start price
20.09.17
/
50%
€87.81
Target price
20.09.17
€76.67
Performance (%)
7.87%
End price
20.09.17
€94.72
Summary
This prediction ended on 20.09.17 with a price of €94.72. The BUY prediction by tamam finished with a performance of 7.87%. tamam has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Alnylam Pharmace. | -1.917% | -1.917% | 20.130% | 47.786% |
| iShares Core DAX® | -6,02 % | -4,60 % | 1,27 % | 48,62 % |
| iShares Nasdaq 100 | 0,51 % | 0,16 % | 14,57 % | 86,13 % |
| iShares Nikkei 225® | -7,16 % | -2,21 % | 28,11 % | 53,17 % |
| iShares S&P 500 | -0,26 % | -0,84 % | 10,20 % | 58,40 % |
Comments by tamam for this prediction
In the thread Alnylam Pharmace. diskutieren
tamam stimmt der Buy-Einschätzung von melinda zu
tamam stimmt am 20.09.2017 der Buy-Einschätzung von melinda mit dem Kursziel 85$ zu.
Überschrift: pharma